Abstract:

Objective To evaluate the role of real-time fluorescence quantitative polymerase chain reaction（PCR）-binding probe in the determination of Mycoplasma pneumoniae（MP）,to analyze the drug resistance mutation of MP,and to guide the clinical medication for children with MP infection. Methods A total of 70 patients with MP infection and 30 patients without MP infection in Fengcheng Hospital of Shanghai Fengxian District from September 2017 to August 2019 were enrolled,and throat swab specimens were collected from children. MP-DNA amplification and fluorescence probe method were used to determine the drug resistance mutation of MP and macrolide antibiotics. The data of children were collected,and the correlation with MP-DNA positive and drug resistance mutation was analyzed. Results The sensitivity and specificity of PCR-binding probe for determining MP were 80.0%（56/70） and 96.7%（29/30）,respectively. The MP-DNA positive determination rate of double serum MP-IgM antibody titer 4 times/4 times higher or lower group was higher than that of single serum titer ≥1:160 group. Sex,age,disease course and history of macrolide antibiotic treatment before admission had no effect on the positive rate of MP-DNA. The MP-DNA drug resistance mutation rate was 85.7%,and the rate of DNA drug resistance mutation in one course of treatment with macrolide antibiotics before admission was 90.5%,which was higher than those of untreated group（80.0%） and the group without finishing one course of treatment（50.0%）. Conclusions Real-time fluorescence quantitative PCR-binding probe can be used as an effective method for MP determination,providing a reference for the clinical use of antibiotics in MP infection children,which has a high clinical application value.

Key words: Mycoplasma pneumoniae, Children, Real-time fluorescence quantitative polymerase chain reaction-binding probe, Drug resistance gene mutation